Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥18
Histologically or cytologically confirmed diagnosis of melanoma (including uveal melanoma) or lung cancer
Treatment with commercial nivolumab for the first time, alone or in combination with ipilimumab, for the approved indications of nivolumab within 14 days before informed consent for this study OR in the case where treatment has not yet been initiated, documentation that the treatment strategy is determined before an informed consent to study participation, and treatment is initiated within 28 days after informed consent
You may not be if
Prior participation in a clinical trial within the past 4 weeks
Previously treated with anti-PD-1, anti-PD-L1, or anti-PD-L2 antibodies
Previously treated with anti-CTLA-4 for lung cancer
Current or pending participation in a clinical trial
Current or pending systemic treatment for cancer other than melanoma and lung cancer
Inability to comply with the study protocol
Clareo Health | Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
